Scipher Hopes IBD Alliance With Galapagos Is The First Of Many

Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.

Abstract matrix digital numbers artifical intelligence ai theme with human face
Scipher uses AI to sort patient data to predict response or non-response to a drug

Artificial intelligence specialist Scipher Medicine  has signed an inflammatory bowel disease collaboration with Galapagos that exemplifies what Scipher is hoping to establish as its business model – repurposing the AI it uses to sift through mountains of clinical-genomic patient data for its diagnostics business to also identify novel targets that may lead to drug therapies for non-responding patients. [Editor's note: This article has been corrected to note that Scipher's patient data are not derived from clinical trials.]

Scipher’s primary business is developing blood tests to enable clinicians to determine which autoimmune disease patients likely will or won’t...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.